DARE press release
Key Highlights
- ➤$851,796 additional grant payment received under existing agreement
- ➤Grant totals approximately $9.9 million received toward up to $10.7 million
- ➤Funding supports non-hormonal intravaginal contraceptive research for LMIC settings
- ➤Future grant funding remains contingent on achieving specified milestones
Expert Statements
Sabrina Martucci Johnson, President and CEO of Daré Bioscience
“We are grateful for the continued support of this important program and its commitment to expanding contraceptive options for women around the world.”
Sabrina Martucci Johnson, President and CEO of Daré Bioscience
“This additional funding will allow us to continue advancing our work toward a novel, non-hormonal intravaginal contraceptive that has the potential to address significant unmet needs and provide women with greater choice and autonomy in their reproductive health.”
SAN DIEGO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that it has received an additional payment of $851,796 under its existing grant agreement.
This payment represents the second-to-last anticipated tranche under the up to approximately $10.7 million grant agreement originally announced in November 2024. The grant funding is supporting Daré Bioscience's ongoing research and development activities focused on identifying and developing a novel non-hormonal intravaginal contraceptive to address unmet needs among women in low- and middle-income country (LMIC) settings, particularly those seeking or preferring non-hormonal contraceptive options.
Get started
Create a free account to read the full story.
